Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
5, 10 and 15 mg drug substance Olanzapine uses oral film dosage form dissolving within seconds without need of water More
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Jul 2007 - 12 pages - $1,100
May 2010 - 58 pages - $795
May 2010 - 60 pages - $795
May 2010 - 60 pages - $795
May 2010 - 60 pages - $795
May 2010 - 60 pages - $795
May 2010 - 60 pages - $795
May 2010 - 60 pages - $795
May 2010 - 57 pages - $795
May 2010 - 60 pages - $795
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us